BAY 80-6946 (Copanlisib)
Binding Mode- Product Name
- BAY 80-6946 (Copanlisib)
- CAS No.
- 1032568-63-0
- Chemical Name
- BAY 80-6946 (Copanlisib)
- Synonyms
- Copanlisib;BAY80-6946;CS-2321;Aliqopa);Copanlisib base;Copanlisib free base;Copanlisib(BAY80-6946);BAY 80-6946 (BAY80-6946;BAY 80-6946 (Copanlisib);BAY 80-6946 (Copanlisib) USP/EP/BP
- CBNumber
- CB52616024
- Molecular Formula
- C23H28N8O4
- Formula Weight
- 480.52
- MOL File
- 1032568-63-0.mol
BAY 80-6946 (Copanlisib) Property
- Density
- 1.51
- storage temp.
- Store at -20°C
- solubility
- insoluble in DMSO; insoluble in H2O; insoluble in EtOH
- form
- solid
- pka
- 8.42±0.20(Predicted)
- color
- Off-white to light brown
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- 20354
- Product name
- Copanlisib
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $61
- Updated
- 2024/03/01
- Product number
- 20354
- Product name
- Copanlisib
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $72
- Updated
- 2023/06/20
- Product number
- 20354
- Product name
- Copanlisib
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $91
- Updated
- 2024/03/01
- Product number
- B119060
- Product name
- BAY80-6946
- Packaging
- 10mg
- Price
- $395
- Updated
- 2021/12/16
- Product number
- BC164810
- Product name
- Copanlisib
- Packaging
- 25mg
- Price
- $450
- Updated
- 2021/12/16
BAY 80-6946 (Copanlisib) Chemical Properties,Usage,Production
Binding Mode
As shown in the co-crystal structure of
copanlisib bound to PI3Kγ, the inhibitor binds with
only one critical hydrogen bond to the amide NH of
Val882 in the adenine pocket, employing the
imidazoline N1 nitrogen (Figs. 1 and 2). In addition,
the C5 aminopyrimidine group fills the affinity pocket,
forming hydrogen bonds with two carboxylic
residues of Asp836 and Asp841 through the amino
group. Finally, the solvent exposed morpholine lies
over Trp812, presumably providing additional
attractive molecular contacts.
Uses
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
Definition
ChEBI: Copanlisib is an imidazoquinazoline that is 2,3-dihydroimidazo[1,2-c]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholin-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is a intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies. It has a role as an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a member of morpholines, an aromatic ether, a diether, a tertiary amino compound, a secondary carboxamide, a pyrimidinecarboxamide, an aminopyrimidine and an imidazoquinazoline.
brand name
Aliqopa
General Description
Class: lipid kinase; Treatment: FL (IV infusion); Other name: BAY 80-6946; Elimination half-life = 52 h (IV); Protein binding = 84.2%
Pharmacokinetics
Copanlisib has poor oral bioavailability due to low permeability and poor solubility, and therefore, it is not suitable for an oral medication. Consequently, it was developed as an IV drug. IV infusion of copanlisib resulted in rapid distribution throughout the body and a prolonged elimination half-life (52 h).
Synthesis
3167-50-8
1032570-74-3
1032568-63-0
Example 10: Step A9: Preparation of copanlisib (10). 1250 g of 7-methoxy-8-[3-(morpholin-4-yl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine, 20.3 kg of N,N-dimethylformamide, 531 g of 2-amino-pyrimidine-5-carboxylic acid, 425 g of N,N-dimethylaminopyridine, and 1000 g of N-[3-(dimethylamino)propyl]-N'-ethylcarbodi N'-ethylcarbodiimide hydrochloride were mixed and the reaction was stirred at room temperature for 17 hours. After completion of the reaction, the reaction mixture was filtered and the solid was collected. The solid was washed with N,N-dimethylformamide followed by ethanol and dried at 50 °C to give 1.6 kg of the target product in 96% yield. The resulting product was directly converted to its dihydrochloride form.
target
pan-PI3K
Metabolism
Copanlisib was the predominant component in
human plasma, accounting for 84% of total
radioactivity AUC, and the morpholinone metabolite
6 was the only circulating metabolite (about 5%).
References
[1] Patent: WO2016/71435, 2016, A2. Location in patent: Page/Page column 55
[2] Patent: WO2016/71426, 2016, A1. Location in patent: Page/Page column 37
[3] Patent: WO2008/70150, 2008, A1. Location in patent: Page/Page column 85
[4] ChemMedChem, 2016, p. 1517 - 1530
BAY 80-6946 (Copanlisib) Preparation Products And Raw materials
Raw materials
Preparation Products
BAY 80-6946 (Copanlisib) Suppliers
- Tel
- --
- Fax
- --
- @pharmaffiliates.com
- Country
- India
- ProdList
- 6754
- Advantage
- 58
- Tel
- --
- Fax
- --
- standards@synzeal.com
- Country
- India
- ProdList
- 6514
- Advantage
- 58
- Tel
- --
- Fax
- --
- mktg@pharmaffiliates.com
- Country
- India
- ProdList
- 6739
- Advantage
- 58
- Tel
- --
- Fax
- --
- sales@ajchem.in
- Country
- India
- ProdList
- 6100
- Advantage
- 58
View Lastest Price from BAY 80-6946 (Copanlisib) manufacturers
- Product
- BAY 80-6946 (Copanlisib) 1032568-63-0
- Price
- US $2.00/kg
- Min. Order
- 1kg
- Purity
- 99%
- Supply Ability
- 100kg
- Release date
- 2018-12-23